Arthritis & Rheumatology · IF 11.4 · Jul 20, 2026 · LoE I
Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial
This phase 3 randomized controlled trial (POETYK PsA-2) tested deucravacitinib, a first-in-class oral selective TYK2 inhibitor, against placebo (with apremilast included only as a safety reference) in 729 adults with active psoriatic arthritis who were biologic-naive or had limited prior TNF inhibitor exposure. By week 16, significantly more patients on deucravacitinib achieved an ACR20 response than those on placebo (54.2% vs 39.4%, p=0.0002), and improvements in joint disease, skin disease (PASI75), physical function (HAQ-DI), and quality of life were sustained through 52 weeks with a stable, well-tolerated safety profile and no new safety signals.
AI summary · from the full text
Why it mattersDeucravacitinib offers an oral, non-biologic option with a novel mechanism (TYK2 regulatory-domain inhibition) and durable 1-year efficacy and safety data for psoriatic arthritis, a disease frequently co-managed by rheumatology and orthopaedic/joint specialists.
Patient-important outcome and adequately powered, offset by more patients lost than the result can absorb and industry funded with author conflicts.